Jack Wei Chieh TanDavid SimJunya AkoWael AlmahmeedMark E. CooperJamshed J. DalalChaicharn DeerochanawongDavid Wei Chun HuangSofian JoharUpendra KaulSin Gon KimNatalie KohAlice Pik Shan KongRungroj KrittayaphongBernard KwokBien J. MatawaranQuang Ngoc NguyenLoke Meng OngJin Joo ParkYongde PengDavid K.L. QuekKetut SuastikaNorlela SukorBoon Wee TeoChee Kiang TeohJian ZhangEugenio B. ReyesSu Yen GohSiriraj HospitalChinese Academy of Medical Sciences & Peking Union Medical CollegeCleveland Clinic Abu DhabiHospital Pulau PinangSeoul National University Bundang HospitalRaja Isteri Pengiran Anak Saleha HospitalUniversity of the Philippines ManilaUniversity of Santo Tomas, ManilaHanoi Medical UniversityNational Yang-Ming University TaiwanUniversitas UdayanaBatra Hospital IndiaKorea University College of MedicineHospital Canselor Tuanku Muhriz UKMNUS Yong Loo Lin School of MedicineShanghai Jiao Tong UniversityVeterans General Hospital-Kaohsiung TaiwanInstitut Jantung Negara Kuala LumpurMonash UniversitySingapore General HospitalPantai Holdings Sdn BhdKitasato UniversityRajavithi HospitalNational Heart Centre, SingaporeFooyin University TaiwanChinese University of Hong KongSengkang General HospitalFarrer Park HospitalKokilaben Hospital2022-08-042022-08-042021-01-01European Cardiology Review. Vol.16, (2021)17583764175837562-s2.0-85105579149https://repository.li.mahidol.ac.th/handle/20.500.14594/78747The Asian Pacific Society of Cardiology convened a consensus statement panel for optimising cardiovascular (CV) outcomes in type 2 diabetes, and reviewed the current literature. Relevant articles were appraised using the Grading of Recommendations, Assessment, Development and Evaluation system, and consensus statements were developed in two meetings and were confirmed through online voting. The consensus statements indicated that lifestyle interventions must be emphasised for patients with prediabetes, and optimal glucose control should be encouraged when possible. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are recommended for patients with chronic kidney disease with adequate renal function, and for patients with heart failure with reduced ejection fraction. In addition to SGLT2i, glucagon-like peptide-1 receptor agonists are recommended for patients at high risk of CV events. A blood pressure target below 140/90 mmHg is generally recommended for patients with type 2 diabetes. Antiplatelet therapy is recommended for secondary prevention in patients with atherosclerotic CV disease.Mahidol UniversityMedicineArticleSCOPUS10.15420/ECR.2020.52